Boosting Cancer Immunity with Radiation Therapy
DNA damage response and cancer immunity
This research explores how specific medications can make radiation therapy more effective at fighting cancer by also strengthening the body's natural immune defenses.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-11120887 on NIH RePORTER |
What this research studies
This project aims to discover how certain medications, called DNA damage response inhibitors (DDRi), can make radiation therapy more effective at destroying cancer cells. These drugs are thought to disable the natural 'brakes' that protect cells, making cancer cells more susceptible to radiation. Researchers are also exploring how these drugs might enhance the body's own immune system to create a stronger, more lasting defense against cancer. The team is using advanced laboratory models to understand these processes in both cancer and immune cells. The hope is to develop new strategies that combine radiation with immune-boosting treatments.
Who could benefit from this research
Good fit: This foundational research is currently focused on laboratory and animal models, so it is not directly recruiting patients for participation at this time.
Not a fit: Patients seeking immediate new treatments would not directly benefit from this early-stage laboratory research, as it is focused on fundamental discoveries.
Why it matters
Potential benefit: If successful, this work could lead to new cancer treatments that combine radiation therapy with immune-boosting drugs, potentially offering more effective and lasting protection against cancer.
How similar studies have performed: Combining radiation with immune-boosting strategies is an active area of research, with other studies showing promise in preclinical and early clinical settings.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Bakkenist, Christopher J. — University of Pittsburgh at Pittsburgh
- Study coordinator: Bakkenist, Christopher J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.